Chronic Obstructive Pulmonary Disease

About Conference

The 18^th International Conference on Chronic Obstructive Pulmonary Disease (COPD 2026) will be held on November 19–20, 2026, in Dubai, UAE, bringing together pulmonologists, respiratory physicians, researchers, clinicians, healthcare professionals, academicians, industry experts, and policymakers from around the world. The conference serves as a premier platform for discussing the latest advancements, emerging technologies, and evidence-based practices in the prevention, diagnosis, treatment, and management of Chronic Obstructive Pulmonary Disease (COPD).

COPD remains one of the leading causes of morbidity and mortality worldwide, affecting millions of individuals and placing a significant burden on healthcare systems. As the prevalence of respiratory diseases continues to rise, there is an increasing need for innovative approaches to early detection, personalized treatment strategies, pulmonary rehabilitation, disease prevention, and patient-centred care.

COPD 2026 will feature keynote presentations, plenary sessions, scientific symposia, panel discussions, poster presentations, and networking opportunities designed to foster collaboration and knowledge exchange among experts across the respiratory healthcare spectrum. The conference will cover a broad range of topics including COPD pathophysiology, risk factors, smoking cessation, pulmonary function testing, respiratory therapies, precision medicine, biomarkers, digital health technologies, clinical trials, comorbidities, pulmonary rehabilitation, and advances in respiratory care.

The event provides a unique opportunity for participants to present their research findings, explore emerging trends, engage with leading experts, and establish valuable professional connections. Through interdisciplinary discussions and scientific collaboration, COPD 2026 aims to accelerate innovation, improve clinical outcomes, and contribute to advancing global lung health.

Join us in Dubai for two days of scientific excellence, professional development, and meaningful discussions shaping the future of COPD research and respiratory healthcare worldwide.

Session & Tracks

1. COPD Epidemiology and Public Health

Chronic Obstructive Pulmonary Disease (COPD) remains a major global health challenge, affecting millions of people and contributing significantly to healthcare costs and mortality. This track explores the epidemiology of COPD, including disease prevalence, incidence, risk factors, demographic trends, and regional variations. Discussions will focus on tobacco exposure, environmental pollution, occupational hazards, socioeconomic determinants, and global health initiatives aimed at reducing disease burden. Topics also include public health policies, disease surveillance, prevention strategies, healthcare accessibility, and the implementation of evidence-based interventions that improve respiratory health across diverse populations.

2. COPD Pathogenesis and Molecular Mechanisms

Understanding the biological processes responsible for COPD is essential for developing effective therapeutic strategies. This session focuses on the molecular and cellular mechanisms involved in chronic airway inflammation, oxidative stress, immune dysregulation, emphysema, airway remodelling, and tissue destruction. Researchers will discuss genetic susceptibility, epigenetic regulation, proteomics, inflammatory pathways, and disease progression. Emerging discoveries in molecular biology continue to provide valuable insights into disease development and identify potential therapeutic targets for future COPD management.

3. Early Diagnosis, Screening and Biomarkers

Early diagnosis is critical for slowing disease progression and improving long-term outcomes. This track examines advances in screening programs, pulmonary function testing, spirometry, imaging technologies, and laboratory biomarkers used for early COPD detection. Discussions include risk assessment, disease classification, precision diagnostics, artificial intelligence-assisted screening, and novel diagnostic tools that support accurate and timely clinical decision-making. Emerging biomarkers also offer promising opportunities for monitoring disease activity and predicting treatment response.

4. Advances in COPD Pharmacotherapy

Continuous innovation in pharmacological treatment has significantly improved COPD management. This session highlights current and emerging therapies including bronchodilators, inhaled corticosteroids, combination inhalers, biologics, anti-inflammatory agents, mucolytic, and novel drug delivery systems. Experts will discuss treatment guidelines, individualized medication strategies, therapeutic optimization, medication adherence, safety considerations, and future drug development designed to improve patient outcomes and quality of life.

5. Pulmonary Rehabilitation and Chronic Care

Pulmonary rehabilitation is a cornerstone of comprehensive COPD management. This track focuses on multidisciplinary rehabilitation programs that improve exercise tolerance, symptom control, functional capacity, and overall well-being. Topics include respiratory physiotherapy, exercise training, nutritional support, breathing techniques, oxygen therapy, patient education, home-based rehabilitation, and long-term disease management strategies. The role of multidisciplinary teams in delivering personalized respiratory care will also be explored.

6. Respiratory Medicine and Pulmonology

Respiratory medicine continues to evolve with advances in clinical practice, diagnostic technologies, and therapeutic interventions. This session provides a comprehensive overview of pulmonary diseases closely associated with COPD, including asthma, bronchiectasis, interstitial lung diseases, pulmonary hypertension, and respiratory failure. Discussions emphasize multidisciplinary approaches to respiratory healthcare, integrated disease management, and innovations that enhance patient care across the spectrum of pulmonary medicine.

7. COPD Phenotypes and Precision Medicine

COPD is a heterogeneous disease requiring individualized treatment approaches. This session explores disease phenotyping, endotyping, biomarker-guided therapy, pharmacogenomics, genetic profiling, and personalized medicine. Advances in precision healthcare enable clinicians to identify distinct patient subgroups and develop targeted treatment strategies that optimize therapeutic outcomes while minimizing unnecessary interventions. The integration of genomic technologies into routine respiratory care will also be discussed.

8. Acute Exacerbations and Intensive Care

Acute exacerbations remain a leading cause of hospitalization and mortality among COPD patients. This track addresses the prevention, diagnosis, and management of exacerbations, including emergency care, respiratory support, mechanical ventilation, intensive care management, oxygen therapy, and post-discharge recovery. Discussions will examine clinical guidelines, infection management, early intervention strategies, and multidisciplinary approaches that reduce hospital readmissions and improve survival.

9. Respiratory Infections and Lung Microbiome

Respiratory infections significantly influence COPD progression and exacerbation frequency. This session examines bacterial, viral, and fungal infections, antimicrobial resistance, vaccination strategies, host immune responses, and the role of the lung microbiome in disease development. Advances in microbiome research are providing new insights into respiratory health and may lead to innovative therapeutic approaches for preventing and managing COPD-related infections.

10. Digital Health, Telemedicine and Artificial Intelligence in COPD

Digital transformation is reshaping respiratory healthcare. This session explores wearable technologies, remote patient monitoring, telemedicine platforms, artificial intelligence, machine learning, predictive analytics, electronic health records, and mobile health applications. Discussions focus on how digital innovations improve disease monitoring, early intervention, treatment adherence, clinical decision-making, and healthcare accessibility while supporting personalized COPD management.

11. Clinical Research and Translational Medicine

Scientific research continues to drive innovation in COPD prevention and treatment. This session highlights clinical trials, translational research, regenerative medicine, stem cell therapy, gene-based approaches, biomarker validation, and novel therapeutic targets. Participants will discuss emerging research methodologies, regulatory considerations, collaborative research networks, and strategies for translating laboratory discoveries into effective clinical applications.

12. COPD Comorbidities and Multidisciplinary Care

Patients with COPD frequently experience multiple chronic conditions that complicate disease management. This track explores cardiovascular disease, diabetes, osteoporosis, anxiety, depression, metabolic disorders, sleep disorders, lung cancer, and other associated comorbidities. Discussions focus on comprehensive patient assessment, multidisciplinary collaboration, integrated healthcare models, and coordinated management strategies that improve overall patient outcomes and quality of life.

13. Environmental Pollution and Occupational Lung Diseases

Environmental and occupational exposures remain important contributors to chronic respiratory disease. This session addresses air pollution, biomass fuel exposure, industrial dust, chemical inhalation, occupational hazards, climate change, and workplace respiratory protection. Discussions emphasize preventive strategies, occupational health policies, environmental monitoring, and public health interventions designed to reduce exposure-related respiratory diseases and improve lung health worldwide.

14. Lung Imaging and Pulmonary Function Technologies

Advances in diagnostic technologies continue to enhance the evaluation of respiratory diseases. This session explores high-resolution computed tomography, magnetic resonance imaging, lung ultrasound, pulmonary function testing, diffusion capacity assessment, artificial intelligence-assisted imaging, and emerging diagnostic platforms. These technologies improve disease detection, severity assessment, treatment planning, and long-term monitoring of patients with COPD and other pulmonary disorders.

15. Future Innovations in COPD and Respiratory Healthcare

Rapid scientific progress is transforming the future of COPD research and clinical practice. This session explores emerging technologies, precision therapeutics, regenerative medicine, digital healthcare solutions, global research collaborations, healthcare policy development, and innovative models of respiratory care delivery. Discussions will focus on future challenges, scientific opportunities, and interdisciplinary partnerships that support improved prevention, diagnosis, treatment, and long-term management of COPD while advancing global lung health.

Market Analysis

Chronic Obstructive Pulmonary Disease (COPD) is one of the fastest-growing healthcare challenges worldwide, affecting more than 390 million people globally and ranking among the top three leading causes of death, according to international health organizations. The increasing prevalence of smoking, exposure to air pollution, occupational hazards, aging populations, and lifestyle-related risk factors continues to drive the demand for improved diagnosis, treatment, and long-term disease management.

The global COPD therapeutics and respiratory care market has experienced substantial growth over the past decade and is projected to continue expanding at a compound annual growth rate (CAGR) of approximately 5–7% through the next decade. Market expansion is supported by increasing healthcare investments, technological advancements in pulmonary diagnostics, the development of novel biologic therapies, precision medicine approaches, digital healthcare solutions, and growing awareness of chronic respiratory diseases.

North America currently represents one of the largest markets for COPD management due to advanced healthcare infrastructure, widespread adoption of innovative therapies, and extensive research funding. Europe continues to play a leading role in respiratory research, supported by collaborative clinical trials, public health initiatives, and favourable reimbursement policies. Meanwhile, the Asia-Pacific region is expected to witness the fastest market growth, driven by rapid urbanization, increasing pollution levels, expanding healthcare access, and a growing elderly population. The Middle East and Africa are also emerging as important markets owing to improvements in healthcare infrastructure and increasing awareness of respiratory diseases.

Recent innovations in inhaled drug delivery systems, biologic therapies, pulmonary rehabilitation programs, artificial intelligence-assisted diagnostics, remote patient monitoring, wearable health technologies, and telemedicine are transforming COPD care. Precision medicine and biomarker-based treatment strategies are further improving patient outcomes by enabling more personalized therapeutic approaches.

The pharmaceutical industry continues to invest significantly in the development of long-acting bronchodilators, combination therapies, anti-inflammatory agents, regenerative medicine, gene-based therapies, and next-generation respiratory devices. Simultaneously, advancements in digital health platforms, predictive analytics, and machine learning are enhancing disease monitoring, treatment adherence, and early intervention.

The increasing burden of COPD has also accelerated collaborations among academic institutions, healthcare organizations, biotechnology companies, pharmaceutical manufacturers, regulatory agencies, and public health authorities. These partnerships are fostering innovation, supporting multicentre clinical research, and facilitating the translation of scientific discoveries into clinical practice.

COPD 2026 provides an ideal international platform for pulmonologists, respiratory physicians, researchers, clinicians, healthcare professionals, industry leaders, policymakers, and academic experts to exchange scientific knowledge, present ground-breaking research, discuss emerging technologies, and explore collaborative opportunities that will shape the future of COPD prevention, diagnosis, treatment, and global respiratory healthcare.